Martín-Guerrero Sandra M, León Josefa, Quiles-Perez Rosa, Belmonte Laura, Martin-Oliva David, Ruiz-Extremera Ángeles, Salmerón Javier, Muñoz-Gámez José Antonio
Biomedical Research Institute of Granada (ibs.GRANADA), Granada. Spain.
Doctoral programme in Regenerative Medicine, Granada University, Granada. Spain.
Curr Med Chem. 2017;24(20):2156-2173. doi: 10.2174/0929867324666170316115039.
Poly(ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme that plays a critical role in diverse cellular functions, such as DNA damage detection and repair, transcriptional regulation and cell death. Furthermore, PARP-1 has emerged as a key player in the pathogenesis of multiple inflammatory diseases and has become a promising target for the treatment of cardiovascular disorders, neurodegenerative diseases and cancer. An increasing body of evidence has linked alterations in the expression levels of PARP-1, enzymatic activity and presence of polymorphism to gastrointestinal malignancies, including oesophageal, gastric, pancreas, liver and colorectal cancers. PARP inhibition has been proposed as a valuable strategy for treating these gastrointestinal disorders. This paper summarises the most significant current literature on the involvement of PARP-1 in gastrointestinal cancer, focusing in particular on its role in the development and occurrence of tumours, providing information about clinical trials and exploring therapeutic possibilities.
聚（ADP-核糖）聚合酶-1（PARP-1）是一种核酶，在多种细胞功能中发挥关键作用，如DNA损伤检测与修复、转录调控和细胞死亡。此外，PARP-1已成为多种炎症性疾病发病机制中的关键因素，并已成为治疗心血管疾病、神经退行性疾病和癌症的一个有前景的靶点。越来越多的证据表明，PARP-1表达水平的改变、酶活性以及多态性的存在与胃肠道恶性肿瘤有关，包括食管癌、胃癌、胰腺癌、肝癌和结直肠癌。PARP抑制已被提议作为治疗这些胃肠道疾病的一种有价值的策略。本文总结了目前关于PARP-1参与胃肠道癌的最重要文献，特别关注其在肿瘤发生发展中的作用，提供有关临床试验的信息并探索治疗可能性。
